Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
Authors Arrieta J, Moina I, Molina J, Gallardo I, Muñiz ML, Robledo C, García O, Vidaur F, Muñoz RI, Iribar I, Aguirre R, Maza A, Mackinnon J
Received 4 February 2014
Accepted for publication 3 April 2014
Published 9 October 2014 Volume 2014:7 Pages 353—359
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Javier Arrieta,1 Iñigo Moina,1 José Molina,2 Isabel Gallardo,3 María Luisa Muñiz,4 Carmen Robledo,5 Oscar García,5 Fernando Vidaur,6 Rosa Inés Muñoz,3 Izaskun Iribar,7 Román Aguirre,7 Antonio Maza8
1Hospital de Basurto, Bilbao, 2Hospital de Donostia, Donostia-San Sebastián, 3Hospital de Galdakao-Usansolo, Galdakao, 4Hospital de Cruces, Baracaldo, 5Hospital de Santiago, Vitoria-Gasteiz, 6Policlínica de Guipúzcoa, Donostia-San Sebastián, 7Hemobesa Clinica Virgen Blanca, Bilbao, 8Dialbilbo, Bilbao, Spain
Aim: The objective of the study reported here was to describe dose equivalence and hemoglobin (Hb) stability in a cohort of unselected hemodialysis patients who were switched simultaneously from epoetin alfa to darbepoetin alfa.
Methods: This was a multicenter, observational, retrospective study in patients aged $18 years who switched from intravenous (IV) epoetin alfa to IV darbepoetin alfa in October 2007 (Month 0) and continued on hemodialysis for at least 24 months. The dose was adjusted to maintain Hb within 1.0 g/dL of baseline.
Results: We included 125 patients (59.7% male, mean [standard deviation (SD)] age 70.4 [13.4] years). No significant changes were observed in Hb levels (mean [SD] 11.9 [1.3] g/dL, 12.0 [1.5], 12.0 [1.5], and 12.0 [1.7] at Months −12, 0, 12 and 24, respectively, P=0.409). After conversion, the erythropoiesis-stimulating agent (ESA) dose decreased significantly (P<0.0001), with an annual mean of 174.7 (88.7) international units (IU)/kg/week for epoetin versus 95.7 (43.4) (first year) and 91.4 (42.7) IU/kg/week (second year) for darbepoetin (65% and 64% reduction, respectively). The ESA resistance index decreased from 15.1 (8.5) IU/kg/week/g/dL with epoetin to 8.1 (3.9) (first year) and 7.9 (4.0) (second year) with darbepoetin (P<0.0001). The conversion rate was 354:1 in patients requiring high (>200 IU/kg/week) doses of epoetin and 291:1 in patients requiring low doses.
Conclusion: In patients on hemodialysis receiving ESAs, conversion from epoetin alfa to darbepoetin alfa was associated with an approximate and persistent reduction of 65% of the required dose. To maintain Hb stability, a conversion rate of 300:1 seems to be appropriate for most patients receiving low doses of epoetin alfa (≤200 IU/kg/week), while 350:1 would be better for patients receiving higher doses.
Keywords: chronic kidney disease, darbepoetin alfa, dose equivalence, epoetin alfa, hemodialysis, hemoglobin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]